Skip to main content

Bimekizumab in Active Psoriatic Arthritis - BE COMPLETE study

BE COMPLETE is published, showing that bimekizumab (BMK), a selective dual inhibitor of interleukin (IL)-17F and IL-17A, results in superior improvement in both skin and joint outcomes in psoriatic arthritis (PsA) patients who have previously failed treatment with a tumour necrosis factor-α (TNFα) inhibitor.

This phase 3, multinational, multicenter, randomised, double-blind, placebo-controlled trial enrolled 400 patients with adult PsA with a history of inadequate response or intolerance to treatment with one or two TNFα inhibitors for either psoriatic arthritis or psoriasis. Patients received subcutaneous BMK 160 mg every 4 weeks or placebo, The primary endpoint was the proportion of patients with an ACR50 response at week 16 (non-responder imputation). Skin responses were measured using the  Psoriasis Area and Severity Index (PASI90) in the patients with active skin involvement (psoriasis affecting at least 3% body surface area at baseline).

Week 16 showed the following responses:

  • ACR50 response: BMK 43% vs PBO 7% (adjusted odds ratio [OR] 11·1 [95% CI 5·4–23·0], p<0·0001)
  • PASI90 response: BMK  69% vs PBO 7% (adjusted OR 30·2 [12·4–73·9], p<0·0001).

There were no new safety signals and no deaths.

These efficacy and safety results with bimekizumab in TNFi-refractory PsA are consistent with previous phase 3 studies in patients with plaque psoriasis.


If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

The author has no conflicts of interest to disclose related to this subject